Vendor, Farmingdale, NY
Codagenix Inc.
UEI TEMNL437K2F1, CAGE 5D8K5
1 award and $0 obligated between February 8, 2024 and March 11, 2026, 100% under full and open competition, against 1.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50123C00048Definitive Contract, February 8, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Conduct a Phase 2B Efficacy Study as Prescribed in AOI15 with Coviliv a Proprietary Live Attenuated Virus Covid-19 Vaccine.NAICS 541714, PSC AN42 | $0 |
- Places of performance
- New York
- Product and service codes
- AN42 Health R&D Services; Health Care - Other; Applied Research
- Transactions
- 6 across 1 awards